Clinical Trials for Cancer Treatment

Study Title:

Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer

What is the purpose of the study? (in Layman's terms, please describe the study)

This study is being done to answer the following question: Can we lower the chance of your colon cancer returning by adding a drug treatment after the usual combination of drugs?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your colon cancer. The usual approach is defined as care most people get for colon cancer.

Upstate Institutional Review Board (IRB) Number:

2098479

Study/Protocol ID:

A022004

Study Phase:

II/III

Patient Age Group:

Adults

Principal Investigator:

Rahul Seth, DO

Who is eligible?

Patients who have colon cancer that was surgically removed but has either spread to nearby lymph nodes or directly extends beyond the bowel wall (also known as stages II and III colon cancer), has a change in the gene called the BRAF gene, and have a functional mismatch repair (MMR) system.

What is involved if I participate?

How long is the study?
6 years
Is transportation provided or reimbursed?
No
Is parking provided or reimbursed?
No
What tests and procedures are involved?
Electrocardiogram, blood samples, scans